The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice
Abstract
Objectives: The overview outlines two decades of research from the European Group for the Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based algorithms for diagnostics and psychopharmacotherapy of treatment-resistant depression (TRD).Methods: The GSRD staging model characterising response, non-response and resistance to antidepressant (AD) treatment was applied to 2762 patients in eight European countries.Results: In case of non-response, dose escalation and switching between different AD classes did not show superiority over continuation of original AD treatment. Predictors for TRD were symptom severity, duration of the current major depressive episode (MDE), suicidality, psychotic and melancholic features, comorbid anxiety and personality disorders, add-on treatment, non-response to the first AD, adverse effects, high occupational level, recurrent disease course, previous hospitalisations, positive family history of MDD, early age of onset and novel associations of single nucleoid polymorphisms (SNPs) within the PPP3CC, ST8SIA2, CHL1, GAP43 and ITGB3 genes and gene pathways associated with neuroplasticity, intracellular signalling and chromatin silencing. A prediction model reaching accuracy of above 0.7 highlighted symptom severity, suicidality, comorbid anxiety and lifetime MDEs as the most informative predictors for TRD. Applying machine-learning algorithms, a signature of three SNPs of the BDNF, PPP3CC and HTR2A genes and lacking melancholia predicted treatment response.Conclusions: The GSRD findings offer a unique and balanced perspective on TRD representing foundation for further research elaborating on specific clinical and genetic hypotheses and treatment strategies within appropriate study-designs, especially interaction-based models and randomized controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An exception is the GSRD staging method 14 , which explicitly defines treatment non- response as a reduction of less than 50% in the total score on the HAM D or the MADRS.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [14]
In the citing paper
“More over, a substantial proportion of them fail mul tiple antidepressant interventions, result ing in what is described as treat ment- resis tant depression (TRD) 5,9- 16 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [14]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 8×
“Department of Psychiatry, Institutio Scientifico H San Raffaele, Milan, Italy In TRD I and TRD II, treatment response was measured according to the Hamilton Rating Scale for Depression (HAMD) (Hamilton 1960) after at least 4 weeks of adequate antidepressant therapy.”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“In TRD III, response was assessed using the Montgomery and Åsberg Depression Rating Scale (MADRS) (Montgomery and Åsberg 1979).”
MethodSelf-citationA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“Furthermore, the Young Mania Rating Scale (YMRS) was applied in all patients to evaluate possible bipolar symptoms and its severity where appropriate (Young et al. 1978).”
MethodVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 5×
“…findings of the GSRD within genes related to neuroplasticity and neuronal cell adhesion proteins PPP3CC, CHL1, GAP43 and ITGB3, but also CREB1 and MAPK1, have been replicated in other samples as STAR D (Trivedi et al. 2006), also yielding interesting results in a pathway analysis (Fabbri et al.”
BackgroundResultInfluentialCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“Twin studies estimated MDD heritability of about 40%, while common variant heritability was more recently estimated to be 9% of heritability (Sullivan et al. 2000; Wray et al. 2018).”
BackgroundeQTLGen, Wray, N. R., 23andMe, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., Adams, M. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0090-3 · Cited by 3,005 · cited 1×
“Twin studies estimated MDD heritability of about 40%, while common variant heritability was more recently estimated to be 9% of heritability (Sullivan et al. 2000; Wray et al. 2018).”
BackgroundGene–environment interactions in psychiatry: joining forces with neuroscience
Caspi, A., & Moffitt, T. E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1925 · Cited by 1,300 · cited 1×
“This sample heterogeneity should be taken into account especially for interpretation of candidate gene studies, which were demonstrated previously to vary according to ethnicity and environmental factors (Caspi and Moffitt 2006; Schosser et al. 2012b).”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“…of switching antidepressant classes over continuation of the ongoing antidepressant treatment is supported by findings in other comparable samples of MDD patients (Ruhe et al. 2006; Rush et al. 2006; Bschor and Baethge 2010; Romera et al. 2012; Schosser et al. 2012b; Bschor et al. 2018).”
Result
Research works printed but not linked: 3
- Thase ME, 1997, J Clin Psychiatry, 58, 23
- Zaninotto L, 2014, Ann Clin Psychiatry, 26, 243
- Zaninotto L, 2013, Ann Clin Psychiatry, 25, 97
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationDefining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
“For example, in Europe, the European Group for the Study of Resistant Depression has published several studies and reviews (Bartova et al., 2019; Kautzky et al., 2019; Schosser et al., 2012; Souery et al., 2007) that have influenced current treatment recommendations of the European Medicines Agency (European Medicines…”
BackgroundSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
Brain-derived neurotrophic factor and mental disorders
Lin, C.-C., & Huang, T.-L. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.01.001 · Cited by 143
“Using machine learning, Val66Met polymorphism along with several other SNPs of various genes could predict antidepressant response [58,59].”
Background
Metadata
- Authors
- Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., Schosser, A., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- King's College London (GB)
- University of Bologna (IT)
- Université Libre de Bruxelles (BE)
- Sheba Medical Center (IL)
- University of London (GB)
- Zentrum für Seelische Gesundheit (AT)
- Corresponding author
- Kasper, Siegfried
- ORCID
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2019-07-03
- Volume
- 20
- Issue
- 6
- Pages
- 427-448
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2962723566
- Cited by
- 152
- References
- 139
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 18 · 2023: 21 · 2022: 24 · 2021: 29 · 2020: 13 · 2019: 3
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The World Journal of Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- GlaxoSmithKline
- H. Lundbeck A/S
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, antidepressant response, predictors of treatment resistance, dose escalation, antidepressant switching, single nucleotide polymorphisms, brain-derived neurotrophic factor, PPP3CC, HTR2A, melancholia, anxiety comorbidity, suicidality, gene expression signatures, psychopharmacological treatment
- MeSH terms
- Machine Learning, Algorithms, Antidepressive Agents, Europe, Humans, Pharmacogenetics, Psychiatric Status Rating Scales, Comorbidity, Treatment Outcome, Polymorphism, Single Nucleotide, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. https://app.cochat.ai/papers/10.1080/15622975.2019.1635270
- The paper
- Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., Schosser, A., & Kasper, S. (2019). Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622975.2019.1635270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.